Size of metabolically abnormal areas of myocardium · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Improvements in quality of life measures · boys with DMD and left ventricular ejection fraction 45% or more
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Size of metabolically abnormal areas of myocardium · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · boys with DMD and left ventricular ejection fraction 45% or more
It is very uncertain whether eplerenone (25 mg daily) changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Change in Ejection fraction (%) · people with DMD or BMD (ages not stated)
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · people with DMD or BMD (ages not stated)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvements in quality of life measures · people with DMD or BMD (ages not stated)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with DMD or BMD (ages not stated)
1 finding from 1 review
Improvements in quality of life measures · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
Prophylactic perindopril (2 mg to 4 mg daily) showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Cardiac function · patients with established cardiomyopathy in DMD
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · patients with established cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvements in quality of life measures · patients with established cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · patients with established cardiomyopathy in DMD
1 finding from 1 review
Change in cardiac function (change in fractional shortening) · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Improvement in symptoms of gastroparesis (short term: 4 to 12 weeks) · symptomatic gastroparesis
1 finding from 1 review
Proportion of people whose symptoms 'improved' (short term: 4 to 12 weeks) · symptomatic gastroparesis
It is very uncertain whether acupuncture changes proportion of people whose symptoms 'improved' (short term: 4 to 12… compared with gastrokinetic agents (very low certainty).
1 finding from 1 review
Proportion of people whose symptoms 'improved' (long term: more than 12 weeks) · symptomatic gastroparesis
It is very uncertain whether acupuncture changes proportion of people whose symptoms 'improved' (long term: more than… compared with gastrokinetic agents (very low certainty).
1 finding from 1 review
Changes of medication for gastroparesis (either short or long term) ‐ not measured · symptomatic gastroparesis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (either short or long term) ‐ not measured · symptomatic gastroparesis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found